Mumbai: Pharma office under Maha GST Dept inspection

Published On 2023-10-27 00:15 GMT   |   Update On 2023-11-01 10:53 GMT

Mumbai: The Maharashtra Goods and Services Tax Department has begun an inspection at Mumbai-based J.B. Chemicals & Pharmaceuticals Limited's Registered office and Corporate office. "We hereby inform you that an inspection pursuant to Maharashtra Goods and Services Tax Act by the Authorities (“GST Department”) had commenced on October 25, 2023 at Company’s Registered office and...

Login or Register to read the full article

Mumbai: The Maharashtra Goods and Services Tax Department has begun an inspection at Mumbai-based J.B. Chemicals & Pharmaceuticals Limited's Registered office and Corporate office. 

"We hereby inform you that an inspection pursuant to Maharashtra Goods and Services Tax Act by the Authorities (“GST Department”) had commenced on October 25, 2023 at Company’s Registered office and Corporate office," JBCPL informed in a recent BSE filing.

"The Company is fully cooperating with the officials of the GST Department and are responding to the queries raised by them," it further stated.

"The business operations of the Company continue as usual and operations are not impacted. The Company will comply with the disclosure requirements from time to time," JB Pharma added.

Read also: JB Pharma secures USFDA nod for anxiety drug

Established in 1976, J.B. Pharma is a pharmaceutical company headquartered in India. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it also manufactures medicated lozenges. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

Read also: JB Chemicals and Pharma Gujarat facility concludes USFDA inspection with zero observations

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News